Medikard s.r.o. — Clinical Trial Site

12 Registered trials

4 Currently recruiting

Organisation

Medikard s.r.o.

Location

Presov, Slovakia

Identifier

ORG-100041982

Address

Kpt. Nalepku 2860/6, 080 01, Slovakia

Departments

#3313: Ambulancia vnútorného lekárstva
#4113: Ambulancia vnútorného lekárstva
2701:Kožná ambulancia Youderm
3354: Kožná ambulancia Youderm
4113: Ambulancia vnútorného lekárstva
9241: Kožná ambulancia Youderm
Ambulancia vnutorneho lekarstva
Kardiologická ambulancia Cardiology outpatient clinic

Clinical trials at this site (12)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden… Pending

2025-523259-72-00 Hidradenitis Suppurativa (HS) 5
An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
Platform study to evaluate the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis Recruiting

2024-519081-49-00 Moderate to severe atopic dermatitis 4 2025-10-28
A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficien… Recruiting

2024-519059-28-00 Chronic Heart Failure 5 2025-07-17
202301CPC Redefine-HF Recruiting

2023-508581-15-00 Heart condition 5 2024-10-08
A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade… Ended

2024-513282-39-00 Hidradenitis Suppurativa (HS) 5 2025-05-28
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit… Ended

2023-508292-37-00 Cardiovascular Disease 5 2020-03-06
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24